Zobrazeno 1 - 10
of 20
pro vyhledávání: '"J Thaddeus Beck"'
Autor:
Gabor Rubovszky, Aditya Bardia, J. Thaddeus Beck, Ross A. Stewart, Mateusz Opyrchal, Melinda L. Telli, Mustafa Khasraw, Smita S. Saraykar, David R. Wise, Mikhail Dvorkin, Anita Scheuber, Rossano Cesari, Panagiotis A. Konstantinopoulos, Anil A. Joy, Timothy A. Yap, Jame Abraham, Colombe Chappey, Matthew D. Galsky, Daria Stypinski
Publikováno v:
Cancer Research. 80:P1-19
Background: Avelumab, a human IgG1 anti–PD-L1 monoclonal antibody, has shown antitumor activity and a manageable safety profile in several tumor types. Talazoparib, an orally available PARP inhibitor, is approved for the treatment of patients with
Autor:
Xavier Pivot, Michelle Miller, Seock-Ah Im, Francisco J. Esteva, Yingbo Wang, Miguel Martin, Arnd Nusch, Luis de la Cruz-Merino, Karen Rodriguez Lorenc, Patrick Neven, Dennis J. Slamon, K. Petrakova, Peter A. Fasching, J. Thaddeus Beck, Stephen Chia, Michelino De Laurentiis, Gena Vidam, Guy Jerusalem, Giulia Val Bianchi, Gabe S. Sonke, Tetiana Taran
Publikováno v:
Journal of Clinical Oncology. 36:2465-2472
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer who were treatment naïve or had received up to one line of pri
Autor:
Cinthia Violeta Hernandez Puente, Ping-Ching Hsu, Lora J. Rogers, Fariba Jousheghany, Eric Siegel, Susan A. Kadlubar, J. Thaddeus Beck, Issam Makhoul, Laura F. Hutchins, Thomas Kieber-Emmons, Behjatolah Monzavi-Karbassi
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology
Frontiers in Oncology
Immune response to a given antigen, particularly in cancer patients, is complex and is controlled by various genetic and environmental factors. Identifying biomarkers that can predict robust response to immunization is an urgent need in clinical canc
Autor:
Nelly Failloux, J. Thaddeus Beck, Robert Daly, Ruth Pettengell, Donald Quick, Kai Hübel, James P Dean, Shaker R. Dakhil, Mariya Pavlyuk, Lowell F Inhorn, David Belada, Pencho Georgiev, David Andorsky
Publikováno v:
Future Oncology. 12:1759-1768
We describe the rationale and design of the ongoing randomized, active-controlled, multicenter, Phase III study evaluating the efficacy of pixantrone and rituximab versus gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or fol
Autor:
J. Thaddeus Beck, Christian U. Blank, Angela Zubel, Adnan Derti, Heidi Nauwelaerts, Carola Berking, Victor Antona, Michael Heinrich, Dirk Schadendorf, Reinhard Dummer, Rupam Ranjan Pal, Sanjiv S. Agarwala, Rob L. H. Jansen, Carla M.L. van Herpen, Axel Hauschild, Paola Queirolo, Paolo A. Ascierto
Publikováno v:
OncoTarget, 10(19), 1850-1859. Impact Journals LLC
Scopus-Elsevier
Oncotarget
Oncotarget, 10, 19, pp. 1850-1859
Oncotarget, 10, 1850-1859
Scopus-Elsevier
Oncotarget
Oncotarget, 10, 19, pp. 1850-1859
Oncotarget, 10, 1850-1859
BRAF and RAS are the most frequently mutated mitogen-activated protein kinase (MAPK) genes in melanoma. Binimetinib is a highly selective MAPK kinase (MEK) 1/2 inhibitor with clinical antitumor activity in NRAS- and BRAFV600-mutant melanoma. We perfo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b26652bb8787171333752b989c125a0
https://www.ncbi.nlm.nih.gov/pubmed/30956763
https://www.ncbi.nlm.nih.gov/pubmed/30956763
Autor:
Melinda L. Telli, Roohi Ismail-Khan, Chiun-Sheng Huang, Sherko Kümmel, Rafael López, Ingrid A. Mayer, J. Thaddeus Beck, Paloma Martín-Martorell, Marina Parton, Shin-Cheh Chen, Aditya Bardia, Daniel Carreon, Laura G. Estévez, Serena Liao, Scott Cameron, Sara A. Hurvitz, Manuel Ruiz-Borrego, Javier Cortes, José Baselga, Sung-Bae Kim
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
Purpose There are currently no targeted therapies approved for triple-negative breast cancer (TNBC). A tumor necrosis factor α ( TNFα)–based gene expression signature (GS) predictive of sensitivity to LCL161, inhibitor of apoptosis antagonist, wa
Autor:
Judith S. Kaur, Kathrin Strasser-Weippl, James N. Ingle, Julie R. Gralow, Keren Sturtz, Alison Stopeck, Kathleen I. Pritchard, Eric P. Winer, J. Thaddeus Beck, Wendy R. Parulekar, Sheldon Rubin, Karen A. Gelmon, Hyman B. Muss, Antonio C. Wolff, Clifford A. Hudis, Dongsheng Tu, Kate Whelan, Nicholas J. Robert, Paul E. Goss, Timothy J. Whelan
Publikováno v:
New England Journal of Medicine. 375:209-219
Canadian Cancer Society Research Institute [021039, 015469]; National Cancer Institute [CA180888, CA189953, CA180828, CA13612, CA37981, CA077202, CA180863, CA67753, CA189805, CA16116, CA180802]; Canadian Cancer Trials Group [CA077202, CA180863]; ECOG
Publikováno v:
Cancer treatment reviews. 69
Metastatic breast cancer (MBC) is the leading cause of cancer-related morbidity and mortality among women worldwide. Endocrine therapy is the standard of care for the most common subtype of MBC, hormone-receptor positive (HR+), human epidermal growth
Autor:
J. Thaddeus Beck, Lasika Seneviratne, Robert William Sweetman, John A. Glaspy, Navneet Dhillon, Chaitali Singh Nangia, Leon Christopher Hwang, Mark S. Chambers, Jennifer K. Litton, J. Randy Sabo, Hope S. Rugo, Timothy F. Meiller, Timothy J. Pluard, Julio A Peguero, Ingrid A. Mayer
Publikováno v:
The Lancet. Oncology. 18(5)
Summary Background Stomatitis is a class effect associated with the inhibition of mTOR and is associated with everolimus therapy for breast cancer. Topical steroids might reduce stomatitis incidence and severity, and the need for dose reductions and
Autor:
Kenneth M. Attie, Elizabeth R. Plimack, Rupal S. Bhatt, Brian I. Rini, Robert S. Alter, J. Thaddeus Beck, Shuchi Sumant Pandya, Matthew L. Sherman, Dawn Wilson, Musa Mutyaba, Xiaosha Zhang, Martin H. Voss, Michael B. Atkins, Chad E. Glasser
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(14)
Purpose: Activin receptor-like kinase 1 (ALK1) is a novel target in angiogenesis. Concurrent targeting of ALK1 and VEGF signaling results in augmented inhibition of tumor growth in renal cell carcinoma (RCC) xenograft models. Dalantercept is an ALK1-